Aclaris Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Aclaris Therapeutics, Inc. (ACRS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ACRS insiders buying or selling?
In the last 12 months, Aclaris Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 1 sale ($1.4M) — net selling of $1.4M. Since April 2018, Trabud has recorded 66 Form 4 filings for ACRS: 23 buys ($12.4M) and 43 sells ($27.4M).
Source: SEC EDGAR Form 4
Key Statistics (April 2018 – Apr 27, 2026)
Total Form 4 filings
66
SEC EDGAR
Insider filers
15
Insider buys (23)
$12.4M
Insider sells (43)
$27.4M
Insider sentiment
Net sellingNet insider flow of $15.0M in net selling since April 2018, and $1.4M in net selling over the last 12 months.
Recent ACRS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Braden Michael Leonard | 10% Owner | Sale | 300.0K | $4.53 | $1.4M | SEC ↗ |
| Nov 20, 2024 | Anand Mehra | Director | Purchase | 666.7K | $2.25 | $1.5M | SEC ↗ |
| Aug 5, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 373.6K | $1.27 | $472.8K | SEC ↗ |
| Jul 31, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 273.7K | $1.31 | $359.0K | SEC ↗ |
| Jul 22, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 154.7K | $1.30 | $201.8K | SEC ↗ |
| Jul 5, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 352.4K | $1.15 | $405.9K | SEC ↗ |
| Jul 1, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 1.5M | $1.13 | $1.7M | SEC ↗ |
| Jun 18, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 545.0K | $1.15 | $628.2K | SEC ↗ |
| Jun 13, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 1.6M | $1.11 | $1.8M | SEC ↗ |
| Mar 5, 2024 | Andrew Kenneth William Powell | Director | Purchase | 14.5K | $1.24 | $18.0K | SEC ↗ |
| Oct 25, 2023 | Joseph Monahan | Chief Scientific Officer | Sale | 6.0K | $5.08 | $30.5K | SEC ↗ |
| Sep 7, 2023 | Kevin Balthaser | Chief Financial Officer | Purchase | 9.5K | $7.90 | $75.0K | SEC ↗ |
| Aug 28, 2023 | James Loerop | Chief Business Officer | Purchase | 14.7K | $6.80 | $100.0K | SEC ↗ |
| Aug 22, 2023 | Joseph Monahan | Chief Scientific Officer | Sale | 6.0K | $7.32 | $43.9K | SEC ↗ |
| Jun 22, 2023 | Joseph Monahan | Chief Scientific Officer | Sale | 6.0K | $10.28 | $61.7K | SEC ↗ |
| Mar 17, 2023 | Douglas J. Manion | Pres and CEO | Purchase | 6.3K | $7.86 | $49.5K | SEC ↗ |
| Mar 9, 2023 | Douglas J. Manion | Pres and CEO | Purchase | 6.5K | $7.74 | $50.3K | SEC ↗ |
| Mar 4, 2023 | Neal Walker | Director | Sale | 59.2K | $12.50 | $740.7K | SEC ↗ |
| Mar 4, 2023 | Joseph Monahan | Chief Scientific Officer | Sale | 30.8K | $12.51 | $385.6K | SEC ↗ |
| Feb 17, 2023 | Joseph Monahan | Chief Scientific Officer | Sale | 5.0K | $13.06 | $65.3K | SEC ↗ |
| Feb 10, 2023 | James Loerop | Chief Business Officer | Sale | 4.3K | $13.89 | $59.3K | SEC ↗ |
| Feb 3, 2023 | Neal Walker | Director | Sale | 30.0K | $16.66 | $499.9K | SEC ↗ |
| Jan 4, 2023 | Neal Walker | Director | Sale | 40.0K | $15.11 | $604.6K | SEC ↗ |
| Dec 16, 2022 | Joseph Monahan | Chief Scientific Officer | Sale | 5.0K | $15.88 | $79.4K | SEC ↗ |
| Nov 14, 2022 | Andrew N Schiff | Director | Sale | 53.9K | $17.05 | $919.6K | SEC ↗ |
Showing the 25 most recent of 66 Form 4 filings for Aclaris Therapeutics, Inc..
Most active ACRS insiders
- Joseph Monahan11 filings
- Neal Walker9 filings
- Braden Michael Leonard8 filings
- Andrew N Schiff6 filings
- Frank Ruffo6 filings
Ask anything about ACRS insider activity
Use Trabud's AI agent to query Aclaris Therapeutics, Inc.'s Form 4 history in plain English — "Show me ACRS CEO purchases this year" or compare it against any other ticker.
Open the AI agentACRS insider trading FAQ
Are Aclaris Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Aclaris Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 1 sale ($1.4M) — net selling of $1.4M. Since April 2018, Trabud has recorded 66 Form 4 filings for ACRS: 23 buys ($12.4M) and 43 sells ($27.4M). Over the full record that is net selling of $15.0M.
How many insiders trade ACRS stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Aclaris Therapeutics, Inc.. The most recent filing was accepted on Apr 27, 2026.
Where does Trabud get ACRS insider trading data?
All ACRS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.